Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
May 18, 2022 07:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the...
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
May 17, 2022 07:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 16:05 ET
|
Diffusion Pharmaceuticals Inc.
Completed Dosing in Altitude Trial; Topline Data Expected in June 2022Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022Ended Quarter with $32.6 Million in Cash, Cash...
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
May 04, 2022 07:20 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
April 18, 2022 09:20 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., April 18, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
April 11, 2022 07:20 ET
|
Diffusion Pharmaceuticals Inc.
Topline data expected within two months Blinded, interim data to be presented at the Undersea & Hyperbaric Medical Society’s Annual Scientific Meeting in May 2022 CHARLOTTESVILLE, Va., April ...
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
April 08, 2022 07:20 ET
|
Diffusion Pharmaceuticals Inc.
• Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T.• No Change to Meeting Location, Record Date, or Proposals to Be Voted Upon CHARLOTTESVILLE, Va., April 08,...
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
March 21, 2022 07:20 ET
|
Diffusion Pharmaceuticals Inc.
Altitude Trial Dosing Expected To Be Completed in 2Q2022; mid-2022 for ILD-DLCO TrialPhase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to Support 2H22 Study Start$37.3M in Cash & Cash...
Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts
February 24, 2022 07:02 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”
December 20, 2021 07:02 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...